<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177461</url>
  </required_header>
  <id_info>
    <org_study_id>502.317</org_study_id>
    <nct_id>NCT02177461</nct_id>
  </id_info>
  <brief_title>Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension</brief_title>
  <official_title>A PROBE (Prospective, Randomised, Open-Label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80mg Once Daily Compared With 10-20 mg Enalapril Once Daily Over a Period of 24 Weeks in Elderly Patients With Blood Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the efficacy and tolerability of Telmisartan 40-80 mg once daily compared&#xD;
      with enalapril 10-20 mg once daily in elderly patients with arterial hypertension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 24-hours mean systolic blood pressure (SBP) (ABPM - ambulatory blood pressure measurement, 24 hours mean represents the average of 24 hourly mean values)</measure>
    <time_frame>Baseline and week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of SBP ABPM tracing profile</measure>
    <time_frame>Week 8 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in trough cuff (sphygmomanometer) SBP</measure>
    <time_frame>Baseline, week 8 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoothness index in comparison with baseline</measure>
    <time_frame>Baseline, week 8 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responders</measure>
    <time_frame>Week 8 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of controlled responders</measure>
    <time_frame>Week 8 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who withdraw due to adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">374</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enalapril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan + clonidine TTS1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enalapril + clonidine TTS1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_label>Telmisartan + clonidine TTS1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <arm_group_label>Enalapril</arm_group_label>
    <arm_group_label>Enalapril + clonidine TTS1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <arm_group_label>Enalapril + clonidine TTS1</arm_group_label>
    <arm_group_label>Telmisartan + clonidine TTS1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 65 years&#xD;
&#xD;
          -  Sitting systolic blood pressure (SBP) ≥ 160 mmHg and any diastolic blood pressure&#xD;
             (DBP) (safety maximum of sitting DBP 110 mmHg), measured by manual cuff&#xD;
             sphygmomanometer at the end of the wash-out period&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary hypertension&#xD;
&#xD;
          -  Malignant hypertension (retinal haemorrhage, exudates or papillary oedema)&#xD;
&#xD;
          -  Clinically significant sodium depletion as defined by serum sodium level &lt; 130 mEq/L,&#xD;
             clinically significant hyperkaliemia as defined by serum potassium level &gt; 5.5 mEq/L,&#xD;
             clinically significant hypokaliemia as defined by serum potassium level &lt; 3.0 mEq/L&#xD;
&#xD;
          -  Atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which&#xD;
             could interfere with the cardiac rhythm&#xD;
&#xD;
          -  Heart rate &lt; 50 bpm&#xD;
&#xD;
          -  Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF&#xD;
             III-IV)&#xD;
&#xD;
          -  Angina pectoris or myocardial infarction&#xD;
&#xD;
          -  Cardiac surgery within the past 3 months prior to start the wash-out period&#xD;
&#xD;
          -  Stroke within the past 6 months prior to start the wash-out period&#xD;
&#xD;
          -  Renal insufficiency defined as creatininaemia &gt; 2mg/dl&#xD;
&#xD;
          -  Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post&#xD;
             renal transplant&#xD;
&#xD;
          -  Liver insufficiency, defined as bilirubinaemia &gt; 2mg/dl and AST (aspartate&#xD;
             aminotransferase) or ALT (alanine-aminotransferase) &gt; twice the upper normal range&#xD;
&#xD;
          -  Clinically significant metabolic and endocrine disease&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Previous history of angioedema&#xD;
&#xD;
          -  Body mass index &gt; 30kg/m2&#xD;
&#xD;
          -  Arm circumference &gt; 32 cm&#xD;
&#xD;
          -  Any condition that may be likely to compromise the trial (alcohol or drug abuse,&#xD;
             disability illness, etc.)&#xD;
&#xD;
          -  Concomitant therapy with antihypertensive drugs non-permitted by protocol, or present&#xD;
             use of tricyclic antidepressant, corticosteroids or drugs known to affect blood&#xD;
             pressure&#xD;
&#xD;
          -  Investigational drug treatment within the past 30 days before the enrolment or&#xD;
             concurrent participation to any other trial&#xD;
&#xD;
          -  Sensitivity, significant adverse reaction or contraindications to the study drugs&#xD;
             (telmisartan, enalapril, clonidine TTS)&#xD;
&#xD;
          -  Predictable lack of patient co-operation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.317_U04-1024.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Enalapril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

